These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 25592111)

  • 1. Synergistic effects of crizotinib and radiotherapy in experimental EML4-ALK fusion positive lung cancer.
    Dai Y; Wei Q; Schwager C; Moustafa M; Zhou C; Lipson KE; Weichert W; Debus J; Abdollahi A
    Radiother Oncol; 2015 Feb; 114(2):173-81. PubMed ID: 25592111
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oncogene addiction and radiation oncology: effect of radiotherapy with photons and carbon ions in ALK-EML4 translocated NSCLC.
    Dai Y; Wei Q; Schwager C; Hanne J; Zhou C; Herfarth K; Rieken S; Lipson KE; Debus J; Abdollahi A
    Radiat Oncol; 2018 Jan; 13(1):1. PubMed ID: 29304828
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ALK inhibitor PF02341066 (crizotinib) increases sensitivity to radiation in non-small cell lung cancer expressing EML4-ALK.
    Sun Y; Nowak KA; Zaorsky NG; Winchester CL; Dalal K; Giacalone NJ; Liu N; Werner-Wasik M; Wasik MA; Dicker AP; Lu B
    Mol Cancer Ther; 2013 May; 12(5):696-704. PubMed ID: 23443800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting stemness is an effective strategy to control EML4-ALK+ non-small cell lung cancer cells.
    Oh SJ; Noh KH; Lee YH; Hong SO; Song KH; Lee HJ; Kim S; Kim TM; Jeon JH; Seo JH; Kim DW; Kim TW
    Oncotarget; 2015 Nov; 6(37):40255-67. PubMed ID: 26517679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of potent ALK inhibitor and its molecular inhibitory mechanism against NSCLC harboring EML4-ALK proteins.
    Kang CH; Yun JI; Lee K; Lee CO; Lee HK; Yun CS; Hwang JY; Cho SY; Jung H; Kim P; Ha JD; Jeon JH; Choi SU; Jeong HG; Kim HR; Park CH
    Biochem Biophys Res Commun; 2015 Aug; 464(3):762-7. PubMed ID: 26168728
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIP1-ALK, a novel ALK fusion variant that responds to crizotinib.
    Fang DD; Zhang B; Gu Q; Lira M; Xu Q; Sun H; Qian M; Sheng W; Ozeck M; Wang Z; Zhang C; Chen X; Chen KX; Li J; Chen SH; Christensen J; Mao M; Chan CC
    J Thorac Oncol; 2014 Mar; 9(3):285-94. PubMed ID: 24496003
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors.
    Sasaki T; Koivunen J; Ogino A; Yanagita M; Nikiforow S; Zheng W; Lathan C; Marcoux JP; Du J; Okuda K; Capelletti M; Shimamura T; Ercan D; Stumpfova M; Xiao Y; Weremowicz S; Butaney M; Heon S; Wilner K; Christensen JG; Eck MJ; Wong KK; Lindeman N; Gray NS; Rodig SJ; Jänne PA
    Cancer Res; 2011 Sep; 71(18):6051-60. PubMed ID: 21791641
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual ALK and EGFR inhibition targets a mechanism of acquired resistance to the tyrosine kinase inhibitor crizotinib in ALK rearranged lung cancer.
    Yamaguchi N; Lucena-Araujo AR; Nakayama S; de Figueiredo-Pontes LL; Gonzalez DA; Yasuda H; Kobayashi S; Costa DB
    Lung Cancer; 2014 Jan; 83(1):37-43. PubMed ID: 24199682
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation of HER family signaling as a mechanism of acquired resistance to ALK inhibitors in EML4-ALK-positive non-small cell lung cancer.
    Tanizaki J; Okamoto I; Okabe T; Sakai K; Tanaka K; Hayashi H; Kaneda H; Takezawa K; Kuwata K; Yamaguchi H; Hatashita E; Nishio K; Nakagawa K
    Clin Cancer Res; 2012 Nov; 18(22):6219-26. PubMed ID: 22843788
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effect and mechanism of silibinin on the inhibition of ALK positive NSCLC cells by sensitizing crizotinib].
    Lin CC; Lu CH; Pan YH; Jiao L; Chen HY; Li L; He Y
    Zhonghua Zhong Liu Za Zhi; 2017 Sep; 39(9):650-656. PubMed ID: 28926892
    [No Abstract]   [Full Text] [Related]  

  • 11. Selective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistance.
    Kodama T; Tsukaguchi T; Yoshida M; Kondoh O; Sakamoto H
    Cancer Lett; 2014 Sep; 351(2):215-21. PubMed ID: 24887559
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amphiregulin triggered epidermal growth factor receptor activation confers in vivo crizotinib-resistance of EML4-ALK lung cancer and circumvention by epidermal growth factor receptor inhibitors.
    Taniguchi H; Takeuchi S; Fukuda K; Nakagawa T; Arai S; Nanjo S; Yamada T; Yamaguchi H; Mukae H; Yano S
    Cancer Sci; 2017 Jan; 108(1):53-60. PubMed ID: 27783866
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Crizotinib: a new treatment option for ALK-positive non-small cell lung cancer.
    O'Bryant CL; Wenger SD; Kim M; Thompson LA
    Ann Pharmacother; 2013 Feb; 47(2):189-97. PubMed ID: 23386065
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of PF-02341066 and radiation on non-small cell lung cancer cells.
    Tumati V; Kumar S; Yu L; Chen B; Choy H; Saha D
    Oncol Rep; 2013 Mar; 29(3):1094-100. PubMed ID: 23254764
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK.
    Katayama R; Khan TM; Benes C; Lifshits E; Ebi H; Rivera VM; Shakespeare WC; Iafrate AJ; Engelman JA; Shaw AT
    Proc Natl Acad Sci U S A; 2011 May; 108(18):7535-40. PubMed ID: 21502504
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A new human lung adenocarcinoma cell line harboring the EML4-ALK fusion gene.
    Isozaki H; Yasugi M; Takigawa N; Hotta K; Ichihara E; Taniguchi A; Toyooka S; Hashida S; Sendo T; Tanimoto M; Kiura K
    Jpn J Clin Oncol; 2014 Oct; 44(10):963-8. PubMed ID: 25170107
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor activity of alectinib, a selective ALK inhibitor, in an ALK-positive NSCLC cell line harboring G1269A mutation: Efficacy of alectinib against ALK G1269A mutated cells.
    Yoshimura Y; Kurasawa M; Yorozu K; Puig O; Bordogna W; Harada N
    Cancer Chemother Pharmacol; 2016 Mar; 77(3):623-8. PubMed ID: 26849637
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of chemokine-mediated angiogenesis in resistance towards crizotinib and its reversal by anlotinib in EML4-ALK positive NSCLC.
    Wang S; Lou N; Luo R; Hao X; Liu Y; Wang L; Shi Y; Han X
    J Transl Med; 2022 May; 20(1):248. PubMed ID: 35642002
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activated MET acts as a salvage signal after treatment with alectinib, a selective ALK inhibitor, in ALK-positive non-small cell lung cancer.
    Kogita A; Togashi Y; Hayashi H; Banno E; Terashima M; De Velasco MA; Sakai K; Fujita Y; Tomida S; Takeyama Y; Okuno K; Nakagawa K; Nishio K
    Int J Oncol; 2015 Mar; 46(3):1025-30. PubMed ID: 25502629
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CT-707 Overcomes Resistance of Crizotinib through Activating PDPK1- AKT1 Pathway by Targeting FAK.
    Liang C; Zhang N; Tan Q; Liu S; Luo R; Wang Y; Shi Y; Han X
    Curr Cancer Drug Targets; 2019; 19(8):655-665. PubMed ID: 30381078
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.